An international, Phase 2, Open-Label, Randomized Study of BGB-311 Combined with Obinutuzumab Compared with Obinutuzumab Monotheraphy in Relapsed/Refractory Follicular Lymphoma

Type of Cancer
Lymphoma

Sponsor
BeiGene

Protocol Number
BGB-3111-212

To Learn More Call
(201)-510-0950